← Back to Search

Virus Therapy

AlloStim for Coronavirus Disease (ALLOPRIME Trial)

Phase 1 & 2

Waitlist Available

Research Sponsored by Immunovative Therapies, Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 0 to day 28

Awards & highlights

ALLOPRIME Trial Summary

This trial tests a new vaccine that could protect elderly adults from any type of viral infection, including COVID-19.

Eligible Conditions

Coronavirus Disease (COVID-19)
Respiratory Syncytial Virus Pneumonia
Acute Respiratory Distress Syndrome
Viral Diseases
Flu
Pneumonia

ALLOPRIME Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 0 to day 28

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 0 to day 28

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0 to day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of subjects able to suppress viral propagation

Proportion of subjects with positive T-cell response

frequency of vaccine events

ALLOPRIME Trial Design

1Treatment groups

Experimental Treatment

Group I: VaccinationExperimental Treatment1 Intervention

ID injection AlloStim Days 0, 3/4, 7, 10/11 and 14

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

AlloStim

2016

Completed Phase 2

~90

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Immunovative Therapies, Ltd.Lead Sponsor

13 Previous Clinical Trials

271 Total Patients Enrolled

Mirror Biologics, Inc.UNKNOWN

2 Previous Clinical Trials

174 Total Patients Enrolled

David Fineberg, MDStudy DirectorMirror Biologics, Inc.

2 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are recruitment efforts for this research still underway?

"Indeed, the clinicaltrials.gov website showcases that this trial is open and looking for patients right now. This specific study was posted on July 12th, 2021 and updated as recently as August 30th, 2022. The researchers need 40 individuals from 4 different areas to complete the trial."

Answered by AI

Could you inform me as to how many research facilities are currently conducting this experiment?

"There are 4 sites where this trial is being conducted: Miami, Tampa, Zephyrhills and additional locations. To reduce the burden of travel, please select the location closest to you."

Answered by AI

How many willing participants are there for this clinical trial?

"Yes, the trial is recruiting patients at this time. The clinical trial was posted on 7/12/2021 and most recently updated on 8/30/2022. They are looking for a total of 40 participants from 4 different locations."

Answered by AI

Recent research and studies

Journal of Translational MedicineJournal

Allo-priming as a Universal Anti-viral Vaccine: Protecting Elderly from Current COVID-19 and Any Future Unknown Viral Outbreak

Har-Noy, Michael, and Reuven Or. 2020. “Allo-priming as a Universal Anti-viral Vaccine: Protecting Elderly from Current COVID-19 and Any Future Unknown Viral Outbreak”. Journal of Translational Medicine. Springer Science and Business Media LLC. doi:10.1186/s12967-020-02363-3.

clinicaltrials.govStudy

Universal Anti-Viral Vaccine for Healthy Elderly Adults

2021. "Universal Anti-Viral Vaccine for Healthy Elderly Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04441047.